Bridgebio Pharma, Inc. (BBIO) — 10-Q Filings
All 10-Q filings from Bridgebio Pharma, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
BridgeBio's Q2 Loss Widens to $143.5M Amid R&D Surge
— Aug 5, 2025 Risk: high
BridgeBio Pharma, Inc. reported a net loss of $143.5 million for the three months ended June 30, 2025, a significant increase from the $105.2 million net loss f -
BridgeBio Pharma Files Q1 2025 10-Q
— Apr 29, 2025 Risk: low
BridgeBio Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations s -
BridgeBio Pharma Q3 2024 Update
— Nov 12, 2024 Risk: medium
BridgeBio Pharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and business operations, includin -
BridgeBio Pharma Files Q2 2024 10-Q
— Aug 1, 2024 Risk: medium
BridgeBio Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business opera -
BridgeBio Pharma, Inc. Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk: medium
BridgeBio Pharma, Inc. (BBIO) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. BridgeBio Pharma, Inc. filed a 10-Q report for the period ending Marc
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX